[Advances in the field of osteoporosis].
Vignot
Emmanuelle
E
Service de Rhumatologie et de Pathologie osseuse, Hôpital Edouard-Heriot, Unité Inserm, Université de Lyon.
Delmas
Pierre D
PD
D015502:Absorptiometry, Photon; D000328:Adult; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002648:Child; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D007006:Hypogonadism / Q000150:complications / Q000188:drug therapy; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D019379:Teriparatide / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007093:Imidazoles; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate; D019379:Teriparatide; D000077211:Zoledronic Acid